Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 93-95

  Ihaddadene, Ryma ^a   Le Gal, Grégoire ^a,b   Delluc, Aurélien ^b   Carrier, Marc ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Hemorrhage; Heparin; Low molecular weight; Neoplasm; Venous thromboembolism; Venous thrombosis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BREAST CANCER; CANCER ASSOCIATED THROMBOSIS; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM; BLOOD; DOSE RESPONSE; MIDDLE AGED; NEOPLASM; PATHOLOGY; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84902539175     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.04.028     Document Type: Article

References (16)

1. J.W. Blom, C.J. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715 722
2. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 2000 809 815
3. B.A. Hutten, M.H. Prins, M. Gent, J.S. Ginsberg, and H.R. Buller Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis J Clin Oncol 18 2000 3078 3083
4. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, and B. Girolami et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
5. L.S. Elting, C.P. Escalante, C. Cooksley, E.B. Avritscher, D. Kurtin, and L. Hamblin et al. Outcomes and cost of deep venous thrombosis among patients with cancer Arch Intern Med 164 2004 1653 1661
6. R.D. Hull, G.F. Pineo, R.F. Brant, A.F. Mah, N. Burke, and R. Dear et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 2006 1062 1072
7. A.Y.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, and M. Prins et al. Low-molecular-weight Heparin versus a coumadin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153
8. G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, and P. Solal-Celigny et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 2002 1729 1735
9. M. Carrier, G. Le Gal, R. Cho, S. Tierney, M. Rodger, and A.Y. Lee Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients J Thromb Haemost 7 2009 760 765
10. C. Luk, P.S. Wells, D. Anderson, and M.J. Kovacs Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy Am J Med 111 2001 270 273
11. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, and B. Brenner et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J Thromb Haemost 11 2013 56 70
12. M. Carrier, A.A. Khorana, J. Zwicker, S. Noble, and A.Y. Lee Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH J Thromb Haemost 11 2013 1760 1765
13. A.Y. Lee Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants Hematology Am Soc Hematol Educ Program 2010 144 149
14. M. Carrier, A.A. Khorana, J.I. Zwicker, G.H. Lyman, G. Le Gal, and A.Y.Y. Lee Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis J Thromb Haemost 10 2012 2599 2601
15. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
16. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, and E.P. Balaban et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 31 2013 2189 2204